![Author ORCID: We display the ORCID iD icon alongside authors names on our website to acknowledge that the ORCiD has been authenticated when entered by the user. To view the users ORCiD record click the icon. [opens in a new tab]](https://chemrxiv.org/engage/assets/public/chemrxiv/images/logos/orcid.png)
Abstract
Due to the good clinical efficacy in treating Novel Coronavirus Pneumonia (NCP) resulted from
SARS-CoV-2, as the traditional Chinese medicine(TCM) prescription, Lianhua Qingwen Formula
(LQF) was composed into the Diagnosis and Treatment Programs of 2019 New Coronavirus
Pneumonia (from fourth to seventh editions) formulated by the National Health Commission of China.
Aiming to prevent and treat viral influenza, LQF was patented from 2003 in China, and passed the
Phase II clinical trial by FDA in the United States in 2015. However, the molecular mechanism of LQF
anti SARS-CoV-2 pneumonia is still not clear. It is shown that the docking scores of three components
in LQF including Rutin, Forsythoside E, and Hyperoside to main protease of SARS-CoV-2 are very
large as -9.1, -9.0 and -8.7 kcal/mol, respectively, which are even better than those of Lopinavir at -7.3
kcal/mol. Importantly, the binding modes between active compounds and protein were verified via
molecular dynamics (MD) simulation and calculation all the binding free energies at MM-PBSA level.
Note that these donor-acceptor systems were stabilized by non-polar interactions including hydrogen
bonds and hydrophobic interactions. At last, from the constructed component-target-pathway network,
it is shown that the components in LQF are related important pathways to improve the human immunity
such as T cell, B cell receptor signaling, natural killer cell mediated cytotoxicity, as well as anti
inflammatory pathways including Fc epsilon RI, ErbB, MAPK signaling and so on. The present
investigation represents the first report on the molecular mechanism of LQF as NCP inhibitor
Supplementary materials
Title
ms lhqw 0321-g SI
Description
Actions
